ClinicalTrials.gg
Active, not recruitingNCT06694753IAVI G004Updated Jul 1, 2026

Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.

A Phase 1 interventional study of mRNA-1645-eODGT8 and mRNA-1645-CoreG28v2 in HIV Infections, sponsored by International AIDS Vaccine Initiative. Active, not recruiting at 6 sites in South Africa. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by International AIDS Vaccine Initiative · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in HIV Infections by International AIDS Vaccine Initiative — none open to participants now, 1 under way, none of them phase 3. HIV Infections · International AIDS Vaccine Initiative.

Planned enrollment
4th of 19
96 · median 65
Started
2025
the only one that year
Phase 1
15 of 19
none open now
Registered
19th of 19
by date

Among the 19 studies in HIV Infections by International AIDS Vaccine Initiative, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 15 in phase 1, and was the 19th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 19 studies in HIV Infections by International AIDS Vaccine Initiative is open now. The open studies under HIV Infections, anywhere →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in HIV Infections by International AIDS Vaccine Initiative as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of mRNAs encoding HIV immunogens (eOD-GT8 60mer, core-g28v2 60mer, N332-GT5 gp151) in adult participants without HIV and in overall good health in South Africa.

Read the detailed description

This study will evaluate the safety and immunogenicity of 3 experimental HIV vaccines in adult participants without HIV and in overall good health in South Africa. The study vaccines are called mRNA-1645-eODGT8, mRNA-1645-CoreG28v2 and mRNA-1645-N332GT5.

The study will be conducted in two parts (Part A and B). Part A will include two Cohorts, each with 2 groups: Cohort 1A Group 1, Cohort 1A Group 2, Cohort 2A Group 3, and Cohort 2A Group 4. Part B will include two Cohorts, each with 2 groups: Cohort 1B Group 5, Cohort 1B Group 6, Cohort 2B Group 7, and Cohort 2B Group 8.

Participants in Part A Cohort 1A will be randomly assigned to receive mRNA-1645-eODGT8 followed by mRNA-1645-CoreG28v2 or to receive placebo. Participants in Part A Cohort 2A will be randomly assigned to receive two doses of the mRNA-1645-N332GT5 vaccine or to receive placebo. Cohorts 1A and 2A in Part A will be enrolled concurrently, and randomization to study product or placebo will take place in each cohort. Depending on their group, participants will receive 10 mcg of mRNA-1645-eODGT8, mRNA-1645-N332GT5 or Placebo by injection at Week 0 and 10 mcg of mRNA-1645-CoreG28v2, mRNA-1645-N332GT5, or Placebo at Week 8.

Participants in Part B Cohort 1B will be randomly assigned to receive an increased dose of the mRNA-1645-eODGT8 and mRNA-1645-CoreG28v2 vaccine or to receive placebo. Participants in Part B Cohort 2B will be randomly assigned to receive an increased dose of the mRNA-1645-N332GT5 vaccine or to receive placebo. Cohorts 1B and 2B in Part B will be enrolled concurrently, and randomization to study product or placebo will take place in each cohort. Depending on their group, participants will receive 30 mcg of mRNA-1645-eODGT8, mRNA-1645-N332GT5 or Placebo by injection at Week 0 and 30 mcg of mRNA-1645-CoreG28v2, mRNA-1645-N332GT5, or Placebo at Week 8.

Additional study visits will occur at Weeks 2, 7.5, 10, 15.5, and 24. Study visits may include physical examinations, medical history, vaccine injections, blood and urine collection, electrocardiogram, leukapheresis, lymph node cell collection, pregnancy test, HIV testing, risk reduction counseling, and questionnaires.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Demonstrates an understanding of the study and is able and willing to complete the process.
  2. 18 to ≤ 55 years old, on day of enrollment.
  3. Available for clinic follow-up through the last clinic visit.
  4. Willingness to undergo FNA and leukapheresis.
  5. Agrees not to enroll in another study of an agent during participation in the trial. If a potential participant is already enrolled in another clinical trial, approvals from the other trial Sponsor and the IAVI Medical Monitor are required prior to enrollment into DESIIGN001/IAVI G004.
  6. In good general health according to the clinical judgment of the Investigator.
  7. Physical examination and laboratory results without findings that would interfere with assessment of safety or reactogenicity in the clinical judgment of the Investigator.
  8. Assessed by clinical staff as having a low likelihood of acquiring per guidelines (see Appendix 4), agrees to discuss their potential for HIV acquisition, agrees to prevention counseling, and agrees to avoid behaviors associated with a higher likelihood of acquiring HIV through the final study visit. "Low likelihood" may include persons stably taking pre-exposure prophylaxis (PrEP) as prescribed in Appendix 4.
  9. (Hgb):

    • ≥12.0 g/dL for AFAB volunteers
    • ≥13.0 g/dL for cisgender AMAB volunteers or for volunteers who have been on masculinizing hormone therapy for more than 6 consecutive months
    • ≥12.0 g/dL for AMAB volunteers who have been on feminizing hormone therapy for more than 6 consecutive months
    • For volunteers who have been on gender-affirming hormone therapy for less than 6 consecutive months, determine Hgb eligibility based on their sex assigned at birth.
  10. White blood cell (WBC) count = 2,500 to 12,000/mm3.
  11. = 125,000 to 550,000/mm3.
  12. (ALT) \<2.5 × upper limit of institutional reference range.
  13. Serum creatinine ≤1.1× (ULN) based on the institutional normal range.
  14. Systolic blood pressure of 90 to \<140 mmHg and diastolic blood pressure of 50 to \<90 mmHg at the screening visit. The average blood pressure between the screening visit and the enrollment visit must be below 140 mmHg systolic and 90 mmHg diastolic. A single measurement ≥160 mmHg systolic or 100 mmHg diastolic during the current study evaluation is exclusionary.
  15. Negative HIV test results by one of the following options:

    • A negative European Conformity (CE)-marked enzyme immunoassay (EIA)
    • A chemiluminescent microparticle immunoassay (CMIA)
    • A negative result on 2 HIV rapid tests (one of these rapid tests must be CE-marked)
  16. Negative for anti- virus (HCV) Abs (anti-HCV) or negative HCV nucleic acid test (NAT) if anti-HCV Abs are detected.
  17. Negative for surface antigen (HBsAg).
  18. For volunteers AFAB or assigned intersex at birth who are capable of becoming pregnant (hereafter referred to as "persons of pregnancy potential"):

    • Must agree to use effective means of from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination time point (see Appendix 5).
    • Must have a negative beta human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on day of enrollment.

    Note: Persons who are NOT of pregnancy potential due to total hysterectomy or bilateral oophorectomy or menopause (no menses for ≥1 year) are not required to undergo pregnancy testing.

  19. Volunteers AFAB or assigned intersex at birth must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination time point.

Exclusion criteria

Exclusion Criteria:

  1. Volunteer is nursing or pregnant.
  2. (BMI) ≥40 kg/m2. Enrollment of individuals with BMI ≥40 kg/m2, whom the site investigator assesses are in good health, may be considered by the IAVI Medical Monitor.
  3. Diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by HgbA1c ≤7% within the last 6 months) or a history of isolated gestational diabetes are not exclusionary. Enrollment of individuals with Type 2 DM that is well controlled on hypoglycemic agent(s) may be considered by the IAVI Medical Monitor on a case-by-case basis, provided that the HgbA1c is ≤8% within the last 6 months (CRC staff may draw these at screening).
  4. Previous or current recipient of an vaccine (previous placebo/control recipients are not excluded).
  5. Receipt of non-HIV investigational vaccine(s) received within the last 1 year. Exceptions include vaccines that have subsequently undergone licensure or Emergency Use Authorization (EUA) by the FDA or World Health Organization (WHO) Emergency Use Listing (EUL), or if outside the US, by the national Regulatory Authority authorizing this clinical trial.
  6. Congenital or acquired immunodeficiency, including systemic medication use likely to impair immune response to vaccine in the opinion of the Investigator, such as use, prednisone ≥10 mg/day within 3 months prior to enrollment.
  7. Blood products or immunoglobulin within 16 weeks prior to enrollment; receipt of immunoglobulin within 16 weeks prior to enrollment requires approval by the IAVI Medical Monitor.
  8. Previous receipt of VRC01 or VRC07-523LS monoclonal antibody (mAb).
  9. Receipt of any vaccine within 4 weeks prior to enrollment or planned receipt within 4 weeks of investigational vaccine administration.
  10. History of myocarditis and/or pericarditis.
  11. A past history of immune-mediated disease, including but not limited to thyroid disease, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, celiac disease, seronegative inflammatory arthritis, systemic sclerosis, and Type 1 diabetes (for other examples, see Appendix 8).
  12. History of or active severe skin conditions, including, but not limited to, cutaneous mastocytosis, psoriasis, atopic dermatitis, lichen planus, hidradenitis suppurativa, bullous pemphigoid, and urticarial vasculitis.
  13. Systemic or local conditions with urticaria as a manifestation, including urticarial vasculitis, maculo-papular cutaneous mastocytosis (formerly urticaria pigmentosa), mast cell activation syndrome, Gleich's syndrome (episodic angioedema with eosinophilia), Well's syndrome (granulomatous dermatitis with eosinophilia/eosinophilic cellulitis), bullous pemphigoid, or adult-onset Still's disease.
  14. Receipt of antigen-based immunotherapy.
  15. Receipt of investigational research agents with a half-life of 7 or fewer days within 4 weeks prior to enrollment. If a potential participant has received investigational agents with a half-life of more than 7 days (or unknown half-life) within the past year, approval by the IAVI Medical Monitor is required for enrollment.
  16. History of serious reaction (eg, , anaphylaxis) to any vaccine or component of the study-vaccine regimen.
  17. History of hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.
  18. History of urticaria and/or dermatographism.
  19. History of atopy (diagnosed or confirmed by a clinician).
  20. Bleeding disorder diagnosed by a clinician that would make study procedures a .
  21. History of seizure(s) within the past 3 years, or if volunteer has used medications to prevent or treat seizure(s) at any time within the past 3 years.
  22. Asplenia or functional asplenia.
  23. Any other chronic or condition that, in the clinical judgment of the Investigator, would jeopardize the safety or rights of the study participant, including but not limited to: clinically significant forms of substance use or alcohol use disorder(s), serious psychiatric disorders, any suicide attempt within the past 1 year (if between 1 and 2 years, consult the IAVI Medical Monitor for approval), or cancer that, in the clinical judgment of the Investigator, has potential for recurrence (excluding basal cell carcinoma).
  24. Asthma (diagnosed or confirmed by a clinician).
  25. History of allergy to local anesthetic (Novocaine, Lidocaine).
  26. Investigator concern for difficulty with venous access based on clinical history and physical examination. For example, persons with a history of intravenous drug use or substantial difficulty with previous blood draws.
  27. Has donated ≥450 mL of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study injection.
  28. Is working or has worked as study personnel or is an immediate family member or house member of study personnel, study site staff, or Sponsor personnel.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Cohort 1A Group 1: mRNA-1645-eODGT8 + mRNA-1645-CoreG28v2

    Participants will receive one injection of 10 mcg mRNA-1645-eODGT8 to be administered as a 0.5 mL IM injection into the deltoid at Week 0 and one injection of 10 mcg mRNA-1645-CoreG28v2 to be administered as a 0.5 mL IM injection into the deltoid at Week 8.

    Biological: mRNA-1645-eODGT8 · Biological: mRNA-1645-CoreG28v2

  • Placebo comparator
    Cohort 1A Group 2: Placebo

    Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Weeks 0 and 8.

    Biological: Placebo

  • Experimental
    Cohort 2A Group 3: mRNA-1645-N332GT5

    Participants will receive 10 mcg of mRNA-1645-N332GT5 to be administered as a 0.5 mL IM injection into the deltoid at Weeks 0 and 8.

    Biological: mRNA-1645-N332GT5

  • Placebo comparator
    Cohort 2A Group 4: Placebo

    Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Week 0 and Week 8.

    Biological: Placebo

  • Experimental
    Cohort 1B Group 5: mRNA-1645-eODGT8 + mRNA-1645-CoreG28v2

    Participants will receive one injection of 30 mcg mRNA-1645-eODGT8 to be administered as a 0.5 mL IM injection into the deltoid at Week 0 and one injection of 30 mcg mRNA-1645-CoreG28v2 to be administered as a 0.5 mL IM injection into the deltoid at Week 8.

    Biological: mRNA-1645-eODGT8 · Biological: mRNA-1645-CoreG28v2

  • Placebo comparator
    Cohort 1B Group 6: Placebo

    Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Week 0 and Week 8.

    Biological: Placebo

  • Experimental
    Cohort 2B Group 7: mRNA-1645-N332GT5

    Participants will receive 30 mcg of mRNA-1645-N332GT5 to be administered as a 0.5 mL IM injection into the deltoid at Weeks 0 and 8.

    Biological: mRNA-1645-N332GT5

  • Placebo comparator
    Cohort 2B Group 8: Placebo

    Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Week 0 and Week 8.

    Biological: Placebo

Interventions

  • BiologicalmRNA-1645-eODGT8

    eOD-GT8 60mer is a self-assembling nanoparticle composed of 60 subunits of the engineered HIV-1 gp120 outer domain germline targeting version 8 (eOD-GT8) fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 15-amino acid Glycine-Serine linker. eOD-GT8 60mer will be delivered using an mRNA lipid nanoparticle (LNP) platform. To be administered by intramuscular (IM) injection at doses of 10 or 30 mcg.

    Also known as: eOD-GT8 60mer mRNA

  • BiologicalmRNA-1645-CoreG28v2

    core-g28v2 60mer is a nanoparticle composed of 60 protein subunits of an engineered core-gp120 fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 21-amino acid Glycine-Serine linker. Core-g28v2 60mer will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.

    Also known as: core-g28v2 60mer mRNA

  • BiologicalmRNA-1645-N332GT5

    N332-GT5 gp151 is an HIV envelope glycoprotein gp151 trimer based on BG505 SOSIP MD39 (clade A) trimer with "germline-targeting" mutations added that confer the ability to bind germline precursors of BG18 class B cells. N332-GT5 gp151 will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.

    Also known as: N332-GT5 gp151 mRNA

  • BiologicalPlacebo

    Saline

    Also known as: Saline, Diluent

06

What researchers measure

Primary outcomes

  1. To assess the incidence of local and systemic reactogenecity and treatment-emergent adverse events [Safety and Tolerability].

    * Local and systemic reactogenicity signs and symptoms will be collected for a minimum of 7 days following receipt of any study vaccination. * AEs leading to early participant withdrawal or permanent discontinuation, SAEs, medically attended adverse events (MAAEs), and AESIs will be collected throughout the study. Additionally, all AEs will be collected for 30 days after any receipt of study vaccination.

    Time frame: Measured a minimum of 7 days following receipt of any study vaccination

  2. To evaluate the induction of VRC01- or BG18-class IgG B cell responses by the vaccine regimens.

    • Proportion of vaccinees with VRC01- or BG18-class IgG B cells, and frequency of VRC01- or BG18-class B cells among IgG+ B cells in PBMCs or in germinal centers, at baseline and after each study product administration, as determined by B-cell phenotyping and BCR sequencing.

    Time frame: V01 [W0, baseline] V04 [W7.5, 7.5 wks. post 1st vacc.] V06 [W10, 2 wks. post 2nd vacc.] V07 [W15.5, 7.5 wks. post 2nd vacc.]

Secondary outcomes

  1. To evaluate vaccine-specific and epitope-specific binding Ab responses elicited by the vaccine regimens.

    Response rate and magnitude of serum IgG binding Abs as assessed by BAMA at baseline and after each study product administration.

    Time frame: Measured at baseline (at Week 0), 2 weeks post 1st vaccination (at Week 2), 7.5 weeks post 1st vaccination (at Week 7.5), 2 weeks post 2nd vaccination (at Week 10), and 7.5 weeks post 2nd vaccination (at Week 15.5)

07

Study locations

6 sites
  • Setshaba Research Centre CRS
    Soshanguve, Gauteng 0152, South Africa
  • Perinatal HIV Research Unit (PHRU)
    Soweto, Gauteng 1862, South Africa
  • CAPRISA eThekwini CRS
    Durban, KwaZulu-Natal 4001, South Africa
  • Isipingo CRS
    Isipingo, KwaZulu-Natal 4110, South Africa
  • Desmond Tutu Health Foundation Emavundleni CRS
    Cape Town, Western Cape 7750, South Africa
  • Desmond Tutu Health Foundation- Groote Schuur Hospital/J52
    Cape Town, Western Cape 7925, South Africa
08

References and documents

Individual participant data

Plan to share: Yes — A primary manuscript will be prepared after the data analysis is available and the results of the study will be published in searchable, peer reviewed scientific literature according to the, allowing unrestricted access and reuse of all peer-reviewed published research.Underlying, anonymized datasets will be made publicly available. The final clinical study report will be made available to the principal investigators. The Sponsor will also provide investigators with the full summary of the study results, which the investigators may share with the study participants and stakeholders, as appropriate.

Supporting information: Study protocol

Time frame: No later than 12 months after the trial completion.

Access criteria: The study data and documents will be shared publicly after the conclusion of the study and at the time of primary manuscript publication. Documentation will include; Study protocols, annotated CRFs and Statistical Analysis Plans. The datasets will be posted as SAS transport files XPT and as CSV files. IAVI will post packages to the Vivli online repository, accessible to the public by website. Vivli uses an independent peer review process to evaluate the validity of external requests.To protect participant privacy and comply with data protection laws, IAVI will utilize an independent organization who specializes in clinical trial data anonymization and privacy to prepare anonymized data packages for public consumption. Manuscripts will be made available at the time of publication through placement in apublicly available repository and openly licensed. Post-publication Data Packages wil be made available at publication in compliance with specific journal requirements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 91 non-industry phase 1 interventional studies under HIV Infections, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's planned 11 months is below that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 19, 2024
StartActual
Dec 15, 2025
Primary completionEst.
Dec 8, 2026
CompletionEst.
Mar 31, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06694753
Lead sponsor
International AIDS Vaccine Initiative
Collaborators
ModernaTX, Inc., The Scripps Research Institute, National Institute of Allergy and Infectious Diseases (NIAID), Bill and Melinda Gates Foundation
Responsible party
Sponsor
First posted
Nov 19, 2024
Start date
Dec 15, 2025
Primary completion
Dec 8, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Linda-Gail Bekker
principal investigator · Desmond Tutu Health Foundation/Center, University of Cape Town

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion